Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
Rattachement africain : sg, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies examining salvage therapies are mostly limited to patients who received chemotherapy-based treatment in frontline without novel agents. We evaluated outcomes in 116 patients with relapsed/refractory (R/R) cHL who received brentuximab and anthracycline-containing frontline treatment. High risk factors at relapse or progression were common, including primary refractory disease (62%), advanced stage (63%), and extranodal disease (46%). At first salvage, 73% of patients received PD-1 blockade (58% in conjunction with chemotherapy), and 81% received PD-1 blockade at any salvage line. Overall, 78% of patients proceeded to ASCT. With a median follow-up of 19 months, the 2-year PFS and OS from the start of salvage in all patients were 61% and 97% respectively. Among patients with ASCT, the 2-year post-transplant PFS (PFS HCT ) was 76% for patients who had PD-1 blockade as salvage before ASCT, compared with 59% for those who did not. In univariate analysis, PD-1 blockade use in first salvage was significantly associated with improved PFS HCT , and this association remained statistically significant after adjusting for stage, extranodal involvement, and primary refractory disease (HR 0.31, p = 0.04). Primary refractory disease after BV-AVD emerged as an ongoing unmet need with a significantly inferior 2-year PFS HCT compared with relapsed patients (58% vs 86%, p = 0.017). Among primary refractory patients who received ASCT, first salvage incorporating a PD-1 blockade showed a trend toward improved PFS HCT compared with non-PD-1 blockade salvage. These results support PD-1 blockade incorporation as preferred first salvage in R/R cHL after BV-containing frontline therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
- Date Crossref
- 25/06/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Singapore General Hospital Department of Haematology pays non établi dans la noticeÉtablissement de santé
-
City of Hope pays non établi dans la noticeÉtablissement de santé
-
Dana-Farber Cancer Institute pays non établi dans la noticeStructure de recherche
-
University of Utah Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Memorial Sloan Kettering Cancer Center pays non établi dans la noticeÉtablissement de santé
-
University of Minnesota Oncology and Transplantation pays non établi dans la noticeUniversité ou école supérieure
-
Mayo Clinic in Arizona Division of Hematology pays non établi dans la noticeÉtablissement de santé
-
Department of Hematology and Hematopoietic Cell Transplantation pays non établi dans la noticeInstitution
-
Dana-Faber Cancer institute pays non établi dans la noticeStructure de recherche
-
Department of Medicine pays non établi dans la noticeInstitution
Department of Haematology — Singapore General Hospital, City of Hope et Dana-Farber Cancer Institute, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.